Survival after HLA-identical allogeneic peripheral blood stem cell and bone marrow transplantation for hematologic malignancies: Meta-analysis of randomized controlled trials

Bone Marrow Transplantation

Volumn 32, Issue 3, 2003, Pages 293-298

  Horan, J T ^a   Liesveld, J L ^a   Fernandez, I D ^a   Lyman, G H ^a   Phillips, G L ^a   Lerner, N B ^a   Fisher, S G ^a  

^a UNIVERSITY OF ROCHESTER SCHOOL OF MEDICINE AND DENTISTRY   (United States)

Author keywords

Allogeneic bone marrow transplantation; Allogeneic peripheral blood stem cell transplantation; Meta analysis

Indexed keywords

BUSULFAN; CYCLOPHOSPHAMIDE; CYCLOSPORIN; ETOPOSIDE; GRANULOCYTE COLONY STIMULATING FACTOR; MELPHALAN; METHOTREXATE; PREDNISONE;

ADULT; ADVANCED CANCER; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ARTICLE; BONE MARROW TRANSPLANTATION; CANCER MORTALITY; CANCER STAGING; CANCER SURVIVAL; CLINICAL TRIAL; CONFIDENCE INTERVAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE ASSOCIATION; DOSE RESPONSE; FEMALE; GRAFT VERSUS HOST REACTION; HEMATOLOGIC MALIGNANCY; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HLA MATCHING; HLA SYSTEM; HUMAN; MAJOR CLINICAL STUDY; MALE; META ANALYSIS; PERIPHERAL BLOOD STEM CELL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RISK ASSESSMENT; WHOLE BODY RADIATION;

ADULT; ANTIGENS, CD34; BONE MARROW TRANSPLANTATION; CELL COUNT; DISEASE PROGRESSION; FEMALE; HEMATOLOGIC NEOPLASMS; HISTOCOMPATIBILITY; HLA ANTIGENS; HUMANS; MALE; MIDDLE AGED; ODDS RATIO; PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; RANDOMIZED CONTROLLED TRIALS; RISK FACTORS; SURVIVAL ANALYSIS; TRANSPLANTATION, HOMOLOGOUS;

EID: 0043171069     PISSN: 02683369     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bmt.1704112     Document Type: Article

References (30)

1. Gratwohl A, Passweg J, Baldomero H, Urbano-Ispizua A. Hematopoietic stem cell transplantation activity in Europe 1999. Bone Marrow Transplant 2001; 27: 899-916.
2. Champlin RE, Schmitz N, Horowitz MM et al. Blood stem cells compared with bone marrow as a source of hematopoietic cells for allogeneic transplantation. IBMTR Histocompatibility and Stem Cell Sources Working Committee and the European Group for Blood and Marrow Transplantation (EBMT). Blood 2000; 95: 3702-3709.
3. Couban S, Simpson DR, Barnett MJ et al. A randomized multicenter comparison of bone marrow and peripheral blood in recipients of matched sibling allogeneic transplants for myeloid malignancies. Blood 2002; 100: 1525-1531.
4. Storek J, Dawson MA, Storer B et al. Immune reconstitution after allogeneic marrow transplantation compared with blood stem cell transplantation. Blood 2001; 97: 3380-3389.
5. Schmitz N, Beksac M, Hasenclever D et al. Transplantation of mobilized peripheral blood cells to HLA-identical siblings with standard-risk leukemia. Blood 2002; 100: 761-767.
6. Bensinger WI, Martin PJ, Storer B et al. Transplantation of bone marrow as compared with peripheral-blood cells from HLA-identical relatives in patients with hematologic cancers. N Engl J Med 2001; 344: 175-181.
7. Blaise D, Kuentz M, Fortanier C et al. Randomized trial of bone marrow versus lenograstim-primed blood cell allogeneic transplantation in patients with early-stage leukemia: a report from the Societe Francaise de Greffe de Moelle. J Clin Oncol 2000; 18: 537-546.
8. Cutler C, Giri S, Jeyapalan S et al. Acute and chronic graft-versus-host disease after allogeneic peripheral-blood stem-cell and bone marrow transplantation: a meta-analysis. J Clin Oncol 2001; 19: 3685-3691.
9. Powles R, Mehta J, Kulkarni S et al. Allogeneic blood and bone-marrow stem-cell transplantation in haematological malignant diseases: a randomised trial. Lancet 2000; 355: 1231-1237.
10. Vigorito AC, Azevedo WM, Marques JF et al. A randomised, prospective comparison of allogeneic bone marrow and peripheral blood progenitor cell transplantation in the treatment of haematological malignancies. Bone Marrow Transplant 1998; 22: 1145-1151.
11. Heldal D, Tjonnfjord G, Brinch L et al. A randomised study of allogeneic transplantation with stem cells from blood or bone marrow. Bone Marrow Transplant 2000; 25: 1129-1136.
12. Guardiola P, Runde V, Bacigalupo A et al. Retrospective comparison of bone marrow and granulocyte colony-stimulating factor-mobilized peripheral blood progenitor cells for allogeneic stem cell transplantation using HLA identical sibling donors in myelodysplastic syndromes. Blood 2002; 99: 4370-4378.
13. Korbling M, Huh YO, Durett A et al. Allogeneic blood stem cell transplantation: peripheralization and yield of donor-derived primitive hematopoietic progenitor cells (CD34 + Thy-1dim) and lymphoid subsets, and possible predictors of engraftment and graft-versus-host disease. Blood 1995; 86: 2842-2848.
14. Morariu-Zamfir R, Rocha V, Devergie A et al. Influence of CD34(+) marrow cell dose on outcome of HLA-identical sibling allogeneic bone marrow transplants in patients with chronic myeloid leukaemia. Bone Marrow Transplant 2001; 27: 575-580.
15. Dominietto A, Lamparelli T, Raiola AM et al. Transplant-related mortality and long-term graft function are significantly influenced by cell dose in patients undergoing allogeneic marrow transplantation. Blood 2002; 100: 3930-3934.
16. Wagner JE, Barker JN, DeFor TE et al. Transplantation of unrelated donor umbilical cord blood in 102 patients with malignant and nonmalignant diseases: influence of CD34 cell dose and HLA disparity on treatment-related mortality and survival. Blood 2002; 100: 1611-1618.
17. Rubinstein P, Carrier C, Scaradavou A et al. Outcomes among 562 recipients of placental-blood transplants from unrelated donors. N Engl J Med 1998; 339: 1565-1577.
18. Laughlin MJ, Barker J, Bambach B et al. Hematopoietic engraftment and survival in adult recipients of umbilical-cord blood from unrelated donors. N Engl J Med 2001; 344: 1815-1822.
19. Petti D. Meta-analysis, Decision Analysis, and Cost-effectiveness Analysis, Oxford University Press: Oxford, 2000.
20. Yusuf S, Peto R, Lewis J et al. Beta blockade during and after myocardial infarction: an overview of the randomized trials. Prog Cardiovasc Dis 1985; 27: 335-371.
21. Mantel N, Haenszel W. Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst 1959; 22: 719-748
22. Breslow N, Day N. in Lyon: International Agency for Research on Cancer (1980).
23. Szydlo R, Goldman JM, Klein JP et al. Results of allogeneic bone marrow transplants for leukemia using donors other than HLA-identical siblings. J Clin Oncol 1997; 15: 1767-1777.
24. Light R, Pillemer D. Summing Up: The Science of Reviewing Research. Harvard University Press: Cambridge, MA, 1984.
25. Mahmoud H, Fahmy O, Kamel A et al. Peripheral blood vs bone marrow as a source for allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplant 1999; 24: 355-358.
26. Schmitz N, Bacigalupo A, Hasenclever D et al. Allogeneic bone marrow transplantation vs filgrastim-mobilised peripheral blood progenitor cell transplantation in patients with early leukaemia: first results of a randomised multicentre trial of the European Group for Blood and Marrow Transplantation. Bone Marrow Transplant 1998; 21: 995-1003.
27. Mackall CL, Fleisher TA, Brown MR et al. Lymphocyte depletion during treatment with intensive chemotherapy for cancer. Blood 1994; 84: 2221-2228.
28. Flowers ME, Parker PM, Johnston LJ et al. Comparison of chronic graft-versus-host disease after transplantation of peripheral blood stem cells versus bone marrow in allogeneic recipients: long-term follow-up of a randomized trial. Blood 2002; 100: 415-419.
29. Mohty M, Kuentz M, Michallet M et al. Chronic graft-versus-host disease after allogeneic blood stem cell transplantation: long-term results of a randomized study. Blood 2002; 100: 3128-3134.
30. Singhal S, Powles R, Treleaven J et al. A low CD34 + cell dose results in higher mortality and poorer survival after blood or marrow stem cell transplantation from HLA-identical siblings: should 2 × 10(6) CD34+ cells/kg be considered the minimum threshold? Bone Marrow Transplant 2000; 26: 489-496.